Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Continuing at fiscal 2007 level

This article was originally published in The Tan Sheet

Executive Summary

FDA and other federal agencies will operate under fiscal 2007 appropriation levels through Nov. 16, according to a continuing resolution passed by Congress on Sept. 27. With no fiscal 2008 appropriations approved by either chamber of Congress as the end of the federal fiscal year approached, House Appropriations Committee Chairman David Obey, D-Wis., on Sept. 25 introduced H. Res. 52 to continue funding government for six weeks. The spending directive for each federal agency would be replaced by its fiscal 2008 appropriation prior to Nov. 16 in the event Congress enacts the legislation before that date, according to H. Res. 52. Like other federal agencies not within the departments of Defense and Homeland Security, FDA's entire fiscal 2007 budget was included in a continuing resolution Congress enacted in February after failing to agree on fiscal 2008 spending levels in separate bills covering the traditional grouping of agencies (1"The Tan Sheet" Feb. 19, 2007, p. 14). House Appropriations Agriculture Subcommittee Chairwoman Rosa DeLauro, D-Conn., in March said the Bush administration's fiscal 2008 budget request for FDA did not reflect the agency's needs (2"The Tan Sheet" March 5. 2007, p. 18)...

You may also be interested in...

FDA 2007 Appropriations For Food, Drug Centers Outstrip Bush Request

FDA's Center for Drug Evaluation and Research and related activities are funded at $567.59 million for fiscal 2007 under the continuing resolution passed by Congress Feb. 14 and signed into law Feb. 15

ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use

The presenter on the MIRASOL study called the data “practice changing,” while the discussant cited Sutro’s STRO-002 as a potential option for patients with low folate receptor alpha expression.

ASCO - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO

Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts